Specific Weight Loss Percentages The company's website also states: These figures are presented as average outcomes but come with an important footnote: "These results include data from patients using both FDA-approved and compounded formulations." This means the reported outcomes combine patients using brand-name Zepbound/Wegovy with those using compounded medications, making it impossible to determine the specific efficacy of the compounded formulations offered through the GLP-1 ID program
Strategies to Protect Bone Health During GLP-1 Treatment Adequate protein intake becomes especially important when taking semaglutide or tirzepatide, as these medications can reduce appetite for all foods including protein-rich sources essential for bone formation
Metabolic changes associated with GLP-1 receptor agonists could theoretically play a role
Hellman U, Karlsson MG, Engstrm-Laurent A, Cajander S, Dorofte L, Ahlm C, et al
Peptides that can help address weight loss and cardiovascular risk factors in research settings include: This novel dual-incretin agonist mimics the function of the incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1)
Molecular Docking: docking experiments were performed using Glide included in the Schrodinger Package, Maestro interface
